Episode 333: Pharmacology 101: CDK Inhibitors
10/18/24 • 35 min
“CDK4/6 inhibition is considered to be a milestone in the realm of targeted breast cancer therapy. The combination of CDK4/6 inhibitors with the endocrine therapy has really emerged as the foremost therapeutic modality for patients diagnosed with hormone receptor–positive, HER2-negative, advanced breast cancer,” ONS member Teresa Knoop, MSN, RN, AOCN®-emeritus, independent nurse consultant in Nashville, TN, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during the latest episode in our series about anticancer drug classes.
Music Credit: “Fireflies and Stardust” by Kevin MacLeod
Licensed under Creative Commons by Attribution 3.0
Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by October 18, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
Learning outcome: Learners will report an increase in knowledge related to CDK inhibitors.
Episode Notes
- Complete this evaluation for free NCPD.
- Oncology Nursing PodcastTM episodes:
- Pharmacology 101 series
- Episode 329: Pharmacology 101: BRAF Inhibitors
- Episode 313: Cancer Symptom Management Basics: Other Pulmonary Complications
- Episode 295: Cancer Symptom Management Basics: Pulmonary Embolism, Pneumonitis, and Pleural Effusion
- Episode 80: Patients Need Checkpoint Inhibitor Education
- Episode 5: New Guidelines for Managing Immunotherapy-Related Adverse Events
- ONS Voice articles:
- Combination CDK4/6 and Fulvestrant Has Survival Benefits in Late-Stage Breast Cancer
- FDA Approves Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-Variant, HR-Positive, HER2-Negative, Advanced Breast Cancer
- FDA Approves Ribociclib With an Aromatase Inhibitor and Ribociclib and Letrozole Co-Pack for Early High-Risk Breast Cancer
- FDA Expands Early Breast Cancer Indication for Abemaciclib With Endocrine Therapy
- FDA Warns of Rare Lung Inflammation With Certain CDK4/6 Inhibitors
- Manage Immunotherapy-Related Diarrhea and Colitis
- Oncology Drug Reference Sheet: Ribociclib
- The Case of the CTCAE Assessment for CDK4/6 Adverse Events
- ONS book: Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition)
- Clinical Journal of Oncology Nursing article: Targeted Therapies: Treatment Options for Patients With Metastatic Breast Cancer
- ONS Symptom Intervention:
“CDK4/6 inhibition is considered to be a milestone in the realm of targeted breast cancer therapy. The combination of CDK4/6 inhibitors with the endocrine therapy has really emerged as the foremost therapeutic modality for patients diagnosed with hormone receptor–positive, HER2-negative, advanced breast cancer,” ONS member Teresa Knoop, MSN, RN, AOCN®-emeritus, independent nurse consultant in Nashville, TN, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during the latest episode in our series about anticancer drug classes.
Music Credit: “Fireflies and Stardust” by Kevin MacLeod
Licensed under Creative Commons by Attribution 3.0
Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by October 18, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
Learning outcome: Learners will report an increase in knowledge related to CDK inhibitors.
Episode Notes
- Complete this evaluation for free NCPD.
- Oncology Nursing PodcastTM episodes:
- Pharmacology 101 series
- Episode 329: Pharmacology 101: BRAF Inhibitors
- Episode 313: Cancer Symptom Management Basics: Other Pulmonary Complications
- Episode 295: Cancer Symptom Management Basics: Pulmonary Embolism, Pneumonitis, and Pleural Effusion
- Episode 80: Patients Need Checkpoint Inhibitor Education
- Episode 5: New Guidelines for Managing Immunotherapy-Related Adverse Events
- ONS Voice articles:
- Combination CDK4/6 and Fulvestrant Has Survival Benefits in Late-Stage Breast Cancer
- FDA Approves Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-Variant, HR-Positive, HER2-Negative, Advanced Breast Cancer
- FDA Approves Ribociclib With an Aromatase Inhibitor and Ribociclib and Letrozole Co-Pack for Early High-Risk Breast Cancer
- FDA Expands Early Breast Cancer Indication for Abemaciclib With Endocrine Therapy
- FDA Warns of Rare Lung Inflammation With Certain CDK4/6 Inhibitors
- Manage Immunotherapy-Related Diarrhea and Colitis
- Oncology Drug Reference Sheet: Ribociclib
- The Case of the CTCAE Assessment for CDK4/6 Adverse Events
- ONS book: Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition)
- Clinical Journal of Oncology Nursing article: Targeted Therapies: Treatment Options for Patients With Metastatic Breast Cancer
- ONS Symptom Intervention:
Previous Episode
Episode 332: Best Nursing Practices for Pain Management in Patients With Cancer
“Nurses really are the professionals who educate how to take these medicines, why we use multimodal therapies, why it isn’t medicine alone—helping patients to understand that pain is a biopsychosocial spiritual phenomenon, and the pills are just going to hit one little aspect of that entire phenomenon,” Judy Paice, PhD, RN, director of the cancer pain program at Northwestern University Feinberg School of Medicine in Chicago, IL, told Lenise Taylor, MN, RN, AOCNS®, BMTCN®, oncology clinical specialist at ONS, during a conversation about nursing practices for cancer pain management.
Music Credit: “Fireflies and Stardust” by Kevin MacLeod
Licensed under Creative Commons by Attribution 3.0
Earn 1 contact hour of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by October 11, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
Learning outcome: Learners will report an increase in knowledge related to managing pain in patients with cancer.
Episode Notes
- Complete this evaluation for free NCPD.
- Oncology Nursing PodcastTM episodes:
- ONS Voice articles:
- ONS book: Clinical Manual for the Oncology Advanced Practice Nurse (fourth edition)
- ONS courses:
- Clinical Journal of Oncology Nursing articles:
- Oncology Nursing Forum articles:
- Barriers for Nurses Providing Cancer Pain Management: A Qualitative Systematic Review
- Framing Cancer Survivors’ Access to and Use and Disposal of Prescribed Opioids Within the Opioid Epidemic
- Interventions for Managing a Symptom Cluster of Pain, Fatigue, and Sleep Disturbances During Cancer Survivorship: A Systematic Review
- ONS Position Statement: Cancer Pain Management
- ONS Learning Library: Pain Management
- Diagnostics article: Diagnosing Pain in Individuals With Intellectual and Developmental Disabilities: Current State and Nove...
Next Episode
Episode 334: Oral Care for Patients With Cancer
“There is an old saying that if you ignore your teeth, they’ll go away. I think that’s a true, true statement. People may think they can get away without daily hygiene. I think that’s kind of important, that you should at least get your teeth taken care of at least once or twice a day by brushing and flossing. I mean this has been proven. Our dental people have really taken the lead on preventive care with oral hygiene in that respect,” Raymond Scarpa, DNP, APN-C, AOCN® clinical program manager of head and neck oncology and supervisory advanced practice nurse in the department of otolaryngology at the Rutgers Cancer Institute of New Jersey at University Hospital in Newark,told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the importance of oral health for patients with cancer.
Music Credit: “Fireflies and Stardust” by Kevin MacLeod
Licensed under Creative Commons by Attribution 3.0
Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by October 25, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
Learning outcome: Learners will report an increase in knowledge related to oral care for patients with cancer.
Episode Notes
- Complete this evaluation for free NCPD.
- Oncology Nursing PodcastTM episodes:
- Episode 269: Cancer Symptom Management Basics: Gastrointestinal Complications
- Episode 116: Screen and Manage Malnutrition in Patients With Cancer
- ONS Voice articles:
- Manage Late Effects From HPV-Positive Oropharyngeal Cancers
- Nursing Considerations for Head and Neck Cancer Survivorship Care
- Research Shows That Vaping Alters Mouth Microbes
- The Case of the Missing Oral Mucositis
- What Advanced Practice Providers Need to Know About Oral Mucositis
- ONS book: Clinical Manual for the Oncology Advanced Practice Nurse (Fourth Edition)
- ONS course: Introduction to Nutrition in Cancer Care
- Clinical Journal of Oncology Nursing articles:
- Dental Care: Unmet Oral Needs of Patients With Cancer and Survivors
- HPV-Positive Oropharyngeal Cancer: The Nurse’s Role in Patient Management of Treatment-Related Sequelae
- Low-Level Laser Therapy: A Literature Review of the Prevention and Reduction of Oral Mucositis in Patients Undergoing Stem Cell Transplantation
- ONS Symptom Interventions: Mucositis
- American Cancer Society
- Oral Cavity (Mouth) and Oropharyngeal (Throat) Cancer
- Palliative Treatment for Oral Cavity and Oropharyngeal Cancer
- Head and Neck Cancer Alliance
To discuss the information in this episode with other oncology nurses, visit the ONS Communities.
To find resources for creating an Oncology Nursing Podcast Cl...
If you like this episode you’ll love
Episode Comments
Generate a badge
Get a badge for your website that links back to this episode
<a href="https://goodpods.com/podcasts/the-ons-podcast-456/episode-333-pharmacology-101-cdk-inhibitors-76487775"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to episode 333: pharmacology 101: cdk inhibitors on goodpods" style="width: 225px" /> </a>
Copy